InThera Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Seed
- Investors
-
4
InThera General Information
Description
Developer of therapeutic vaccines designed to treat infectious diseases. The company offers recombinant proteins and virus-like particle vaccines using E. coli-based VLP technology to improve wellness through innovative protein biotechnology, enabling medical professionals to treat norovirus, hand, foot, and mouth disease virus.
Contact Information
Website
inthera.co.krCorporate Office
- B-218, 11, Beobwon-ro 11-gil
- Songpa-gu
- Seoul
- South Korea
Corporate Office
- B-218, 11, Beobwon-ro 11-gil
- Songpa-gu
- Seoul
- South Korea
InThera Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Seed Round | 01-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | 14-Sep-2018 | Completed | Clinical Trials - Phase 1 | |||
| 1. Accelerator/Incubator | 01-Jun-2017 | Completed | Clinical Trials - Phase 1 |
InThera Patents
InThera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024251398-A1 | Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor | Pending | 14-Apr-2023 | ||
| EP-4696702-A1 | Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor | Pending | 14-Apr-2023 | ||
| US-20260284173-A1 | Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor | Pending | 14-Apr-2023 | ||
| WO-2024215140-A1 | Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor | Inactive | 14-Apr-2023 | ||
| AU-2021282837-A1 | Recombinant expression vector for producing encapsulin-based vaccine, and preparation method therefor | Active | 01-Jun-2020 | A61P31/12 |
InThera Signals
InThera Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| GeneN Investment Partners | Venture Capital | Minority | ||
| InterVest | Venture Capital | Minority | ||
| Tech Incubator Program for Startup | Accelerator/Incubator | |||
| Bluepoint | Venture Capital | Minority |
InThera FAQs
-
When was InThera founded?
InThera was founded in 2016.
-
Where is InThera headquartered?
InThera is headquartered in Seoul, South Korea.
-
What is the size of InThera?
InThera has 13 total employees.
-
What industry is InThera in?
InThera’s primary industry is Drug Discovery.
-
Is InThera a private or public company?
InThera is a Private company.
-
What is InThera’s current revenue?
The current revenue for InThera is .
-
How much funding has InThera raised over time?
InThera has raised $446K.
-
Who are InThera’s investors?
GeneN Investment Partners, InterVest, Tech Incubator Program for Startup, and Bluepoint have invested in InThera.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process